Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) PT Raised to $62 at H.C. Wainwright
November 7, 2017 2:02 PM ESTH.C. Wainwright analyst Edward White raised his price target on Acceleron Pharma (NASDAQ: XLRN) to $62.00 (from $57.00) while maintaining a Buy rating.
White notes Luspatercept and Sotatercept updates expected at ASH.
... MoreAcceleron Pharma (XLRN) Misses Q3 EPS by 1c
November 7, 2017 7:07 AM ESTAcceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.65), $0.01 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.82 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
... More